Entsar Hadi Jawad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Entsar Hadi Jawad has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alhasan Ali Jabbar
Department of Pharmacology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia
1 shared publication - Ashti M H Saeed
Department of Pharmaceutics, College of Pharmacy, Mustansiriyah University, Baghdad, 10011, Iraq
1 shared publication - Hany Akeel Al-Hussaniy
Department of Pharmacology, College of Pharmacy, Al-nisour University, Baghdad, Iraq
1 shared publication - Hasanain Shakir Mahmood
Department of Pharmaceutics, College of Pharmacy, University of Alkafeel, Najaf 54001, Iraq
1 shared publication - Hassan A. Almoustafa
Universiti Malaya Research Center for Biopharmaceuticals and Advanced Therapeutics (UBAT), Pharmacology Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
1 shared publication - Istabraq Saeed Abaas
College of Dentistry, Alzahrawi University, Karbela, Iraq
1 shared publication
Latest Publications
- 30 September 2026
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 2026 (9) , 2186-2193
Formulation and Characterization of Lipophilic Chemotherapy as Ethosomal Gel for Cervical Cancer
Aim: methotrexate was formulated as Ethosomal gel for enhancing the therapeutic performance and stability to treat cervical cancer via targeting the drug locally through cervical mucosa to avoid the systemic adverse effect of the chemotherapy. Materials and Methods: The formulations were produced using phospholipid and cholesterol then evaluated for particle size, polydispersity index, zeta potential, pH and drug release. The optimized ethosome formula then converted to gel. The gel evaluated for organoleptic properties, pH, viscosity and permeability. Results: The results showed than F8 was the best ethosomal formula with 34nm in size and 92% entrapment efficiency. This formula converted into gel had 1% gelling agent that was optimized ethosomal gel formula and gave better release that ordinary methotrexate gel with same type and percent of gelling agent. Conclusions: The drug was successfully formulated as ethosomal gel for treating cervical cancer topically in order to avoid the systemic exposure for the chemotherapy and its consequence adverse effect.
- 30 September 2026
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 2026 (9) , 2186-2193
Formulation and Characterization of Lipophilic Chemotherapy as Ethosomal Gel for Cervical Cancer
Aim: methotrexate was formulated as Ethosomal gel for enhancing the therapeutic performance and stability to treat cervical cancer via targeting the drug locally through cervical mucosa to avoid the systemic adverse effect of the chemotherapy. Materials and Methods: The formulations were produced using phospholipid and cholesterol then evaluated for particle size, polydispersity index, zeta potential, pH and drug release. The optimized ethosome formula then converted to gel. The gel evaluated for organoleptic properties, pH, viscosity and permeability. Results: The results showed than F8 was the best ethosomal formula with 34nm in size and 92% entrapment efficiency. This formula converted into gel had 1% gelling agent that was optimized ethosomal gel formula and gave better release that ordinary methotrexate gel with same type and percent of gelling agent. Conclusions: The drug was successfully formulated as ethosomal gel for treating cervical cancer topically in order to avoid the systemic exposure for the chemotherapy and its consequence adverse effect.
- Open Access
- 12 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
A review on nanotechnology in drug delivery systems for cancer therapy
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.
- 12 May 2026
- Published by Pensoft Publishers in Pharmacia
- Vol. 73
Open AccessA review on nanotechnology in drug delivery systems for cancer therapy
Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.